(Q44188968)

English

The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant. Potential implications for CYP2D6 phenotyping studies and the clinical use of CYP2D6 substrate drugs in some African populations

scientific article published in November 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant. Potential implications for CYP2D6 phenotyping studies and the clinical use of CYP2D6 substrate drugs in some African populations (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

author name string

Tashinga E Bapiro

1

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Julia A Hasler

2

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Marianne Ridderström

3

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Collen M Masimirembwa

4

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

language of work or name

0 references

publication date

1 November 2002

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Biochemical Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

64

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

1387-1398

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Human cytochrome P450s: selectivity and measurement in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

Genetic polymorphism of drug metabolising enzymes in African populations: implications for the use of neuroleptics and antidepressants

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

Propranolol disposition in Chinese subjects of different CYP2D6 genotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

Formation of morphine from codeine in Chinese subjects of different CYP2D6 genotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

Ethnic differences in drug disposition and responsiveness

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in southern California

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

Improved method for high efficiency transformation of intact yeast cells

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

Efficient high-performance liquid chromatographic assay for the simultaneous determination of metoprolol and two main metabolites in human urine by solid-phase extraction and fluorescence detection

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

Competitive CYP2C9 inhibitors: enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

Development and validation of a genetic algorithm for flexible docking

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, P450 102, and P450 108

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

The Substrate Binding Site of Human Liver Cytochrome P450 2C9: An NMR Study†

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

The catalytic pathway of cytochrome p450cam at atomic resolution

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

Pharmacogenetics and psychopharmacotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

The influence of CYP2D6 polymorphism on the antiarrhythmic efficacy of propafenone in patients with paroxysmal atrial fibrillation during 3 months propafenone prophylactic treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

Defective hydroxylation of bufuralol associated with side-effects of the drug in poor metabolisers [letter]

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

Oxidation phenotype--a major determinant of metoprolol metabolism and response

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Danish University Antidepressant Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

Tricyclic plasma levels. Effect of age, race, sex, and smoking

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

CYP2D6 polymorphism in a Gabonese population: contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

A model for human cytochrome P450 2D6 based on homology modeling and NMR studies of substrate binding

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: structural studies on specific CYP2D6 substrate metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

The CYP2 family: models, mutants and interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

Influence of amino acid residue 374 of cytochrome P-450 2D6 (CYP2D6) on the regio- and enantio-selective metabolism of metoprolol

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

Novel approach to predicting P450-mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

A predictive model for substrates of cytochrome P450-debrisoquine (2D6)

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

2 Modeling of mammalian P450s on basis of P450cam x-ray structure

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

Regioselective hydroxylation of debrisoquine by cytochrome P4502D6: implications for active site modelling

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of substrate metabolism by wild type CYP2D6 protein and a variant containing methionine, not valine, at position 374.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901351-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0006-2952(02)01351-5

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44188968&oldid=2108365834"